PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
Psyomics's investors include Parkwalk Advisors, Martlet Capital, EISMEA, University of Cambridge Enterprise, Association of British Healthcare Industries.
Psyomics is headquartered in Cambridge, United Kingdom.
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
Psyomics is at the Non-equity Assistance stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Psyomics — Funding & Investors." VCBacked, April 16, 2025, https://www.vcbacked.co/company/psyomics. Accessed October 18, 2026.
VCBacked. (2025). Psyomics — Funding & Investors. Retrieved October 18, 2026, from https://www.vcbacked.co/company/psyomics
{{cite web |title=Psyomics — Funding & Investors |url=https://www.vcbacked.co/company/psyomics |website=VCBacked |access-date=October 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated